Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease
source: St. Jude Children’s Research Hospital
year: N/A
summary/abstract:Bone marrow (stem cell) transplants have been used for the treatment and cure of a variety of cancers, immune system diseases, and blood diseases for many years. Doctors in the United States and other countries have developed studies to treat children who have severe sickle cell disease with bone marrow (stem cell) transplants.
In a person with sickle cell disease, the bone marrow produces red blood cells that contain hemoglobin S. This leads to the complications of sickle cell disease.
• To prepare for a bone marrow (stem cell) transplant, strong medicines, called chemotherapy, are used to weaken or destroy the patient’s own bone marrow, stem cells, and infection fighting system.
– This is done so the patient does not reject the new blood cells coming from the donor.
• The patient’s bone marrow then is replaced with blood-forming stem cells from a donor who does not have sickle cell disease.
– This can be a donor with normal hemoglobin or sickle cell trait.
– The actual transplant is given like a blood transfusion through an IV tube.
read more
+myBinderRelated Content
-
Diabetes Drug, Metformin, Suggested as ‘Breakthrough’ Treatment for Sickle Cell AnemiaMetformin, a common drug for Type 2 diab...
-
Pharmacologic Therapies for Sickle Cell DiseaseSickle cell disease (SCD) is a multisyst...
-
Hospitals See No Link Between US Opioid Crisis and Patients’ Use of Treatment, Study ReportsThe U.S. opioid epidemic is not linked t...
-
SCD Patients Receiving Hydroxyurea in the U.S. Still Face Many ChallengesPeople with sickle cell disease (SCD) tr...
-
Prevention of acute sickle cell crisis: review of the NEJM reportA recent article in the New England Jour...
-
Johns Hopkins researchers offer new protocol to potentially cure sickle cell diseaseThere's new hope for patients who have b...
-
Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell DiseaseImara Inc. today announced it will repor...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.